(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

Virginia will be home to a workforce training center preparing thousands of people each year for a career in the pharmaceutical industry.

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving ...

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.